- Home
- DX vs ETNB Comparison
DX vs ETNB Comparison
Compare DX & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- ETNB
- Stock Information
- Founded
- DX 1987
- ETNB 2018
- Country
- DX United States
- ETNB United States
- Employees
- DX N/A
- ETNB N/A
- Industry
- DX Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- DX Real Estate
- ETNB Health Care
- Exchange
- DX Nasdaq
- ETNB Nasdaq
- Market Cap
- DX 984.9M
- ETNB 867.4M
- IPO Year
- DX N/A
- ETNB 2019
- Fundamental
- Price
- DX $12.45
- ETNB $9.19
- Analyst Decision
- DX Strong Buy
- ETNB Buy
- Analyst Count
- DX 5
- ETNB 7
- Target Price
- DX $13.33
- ETNB $30.33
- AVG Volume (30 Days)
- DX 2.1M
- ETNB 966.7K
- Earning Date
- DX 10-21-2024
- ETNB 11-07-2024
- Dividend Yield
- DX 14.35%
- ETNB N/A
- EPS Growth
- DX 1170.16
- ETNB N/A
- EPS
- DX 1.22
- ETNB N/A
- Revenue
- DX $123,176,000.00
- ETNB N/A
- Revenue This Year
- DX N/A
- ETNB N/A
- Revenue Next Year
- DX $2,132.79
- ETNB N/A
- P/E Ratio
- DX $10.23
- ETNB N/A
- Revenue Growth
- DX 172.15
- ETNB N/A
- 52 Week Low
- DX $11.36
- ETNB $7.00
- 52 Week High
- DX $13.13
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- DX 51.35
- ETNB 59.82
- Support Level
- DX $12.42
- ETNB $8.90
- Resistance Level
- DX $12.60
- ETNB $9.71
- Average True Range (ATR)
- DX 0.14
- ETNB 0.55
- MACD
- DX 0.01
- ETNB 0.05
- Stochastic Oscillator
- DX 58.33
- ETNB 75.59
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including residential MBS and commercial MBS.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).